Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorGardner, John S.en_US
dc.date.accessioned2012-06-15T20:16:49Z
dc.date.issued1994en_US
dc.identifier.citationPROFIT WINDFALL OR PATIENT WINDFALL? The Orphan Drug Act and Proposals for its Reform (1994 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8889434
dc.description.abstractThe Orphan Drug Act is a statute with a noble purpose but a controversial history. Originally designed to spur research into drugs for conditions with extremely limited patient populations,~ the Act has become a highly successful means of developing new drugs for rare diseases and conditions. In total, these conditions affect a significant percentage of the population -- as many as 1 out of every 13 Americans. In the ten years prior to the Act's passage, only ten drugs had been approved for these conditions, but by December 31, 1993, 569 drugs had received designation as orphan drugs under the Act; of these, over 65 had been approved. Few, then, would dispute that for its intended purpose -- benefit to patients suffering from rare conditions -- the Act has worked successfully.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectOrphan Drug Acten
dc.subjecthuman growth hormoneen
dc.subjecterythropoietinen
dc.subjectEPOen
dc.subjectpentamidineen
dc.subjectGenentechen
dc.titlePROFIT WINDFALL OR PATIENT WINDFALL? The Orphan Drug Act and Proposals for its Reformen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-06-15T20:16:49Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record